Anamarija Jurisic, Pei-Ju Sung, Mark Wappett, Julien Daubriac, Ian T Lobb, Wei-Wei Kung, Nyree Crawford, Natalie Page, Eamon Cassidy, Stephanie Feutren-Burton, J S Shane Rountree, Matthew D Helm, Colin R O'Dowd, Richard D Kennedy, Gerald Gavory, Aaron N Cranston, Daniel B Longley, Xavier Jacq, Timothy Harrison
BACKGROUND: Understanding how to modulate the microenvironment of tumors that are resistant to immune checkpoint inhibitors represents a major challenge in oncology.Here we investigate the ability of USP7 inhibitors to reprogram the tumor microenvironment (TME) by inhibiting secretion of vascular endothelial growth factor (VEGF) from fibroblasts. METHODS: To understand the role played by USP7 in the TME, we systematically evaluated the effects of potent, selective USP7 inhibitors on co-cultures comprising components of the TME, using human primary cells...
April 2024: Clinical and Translational Medicine